Recombinant Human Sialidase-1 Protein，His

Sialidase-1, also known as neuraminidase-1 (NEU1), is an important enzyme that catalyzes the removal of sialic acid residues from glycoconjugates, playing a crucial role in cellular processes such as cell signaling, pathogen recognition, and immune responses. Mutations or deficiencies in the NEU1 gene are linked to sialidosis and other lysosomal storage disorders, which can lead to severe neurological symptoms, developmental delays, and other metabolic issues. Research on recombinant Sialidase-1 protein focuses on its biosynthesis, structural characterization, and functional analysis to understand its role in various biological processes and disease mechanisms. The production of recombinant NEU1 provides an opportunity for therapeutic applications, including enzyme replacement therapy, to alleviate symptoms associated with NEU1 deficiencies. Recent advancements in protein engineering and expression systems have facilitated the development of highly active and stable recombinant forms of the enzyme, paving the way for potential clinical interventions. Additionally, understanding the enzymatic mechanisms and substrate specificity of sialidase-1 may lead to innovative strategies for targeting diseases related to glycan metabolism and provide insights into the broader implications of sialylation in health and disease. Overall, ongoing research aims to harness the therapeutic potential of recombinant Sialidase-1 in treating sialidosis and other related conditions while advancing our understanding of the critical roles that sialic acid plays in cellular functions and pathogenicity.